biotech · Ataxia Telangiectasia · Ataxia Telangiectasia (A-T) · QNCX
Quince Therapeutics
Quince Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2012
- Employees
- 21
- Programs
- 10
- Drugs
- 8
- Patents
- 1
Quince Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Quince Therapeutics.
Quince Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Dexamethasone
Quince Therapeutics
Crohn's Disease
1 trial -
Dexamethasone sodium phosphate
Quince Therapeutics
Ataxia Telangiectasia
2 trials -
Dexamethasone sodium phosphate for encapsulation into autoerythrocytes
Quince Therapeutics
Ataxia Telangiectasia (A-T)
1 trial -
EryDex Low dose DSP
Quince Therapeutics
Nervous System Disease
1 trial -
EryDex System
Quince Therapeutics
Ataxia Telangiectasia
1 trial -
IEDAT-04-2022
Quince Therapeutics
Ataxia Telangiectasia
1 trial
Frequently asked questions
How many clinical projects does Quince Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.